Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world.
Edoardo CaronnaVictor José GallardoGabriella EgeoManuel Millán VázquezCandela Nieves CastellanosJavier A MembrillaGloria VaghiJoana Rodríguez-MontolioNeus Fabregat FabraFrancisco Sánchez-CaballeroAlex Jaimes SánchezAlbert Muñoz-VendrellRenato OliveiraGabriel GárateYésica González-OsorioDaniel Guisado-AlonsoRaffaele OrnelloCem ThunstedtIris Fernández-LázaroMarta Torres-FerrúsAlicia AlpuentePaola TorelliCinzia AuriliaRaquel Lamas PéreMaria José Ruiz CastrilloRoberto De IccoGrazia SancesSarah BroadhurstHui Ching OngAndrea Gómez GarcíaSergio CampoyJordi SanahujaGonçalo CabralIsabel Beltrán BlascoMarta Waliszewska-ProsółLiliana PereiraAlmudena Layos-RomeroIsabel LuzeiroLaura DoradoMaría Rocio Álvarez EscuderoArne MayAlba López-BravoIsabel Pavão MartinsChristina SundalPablo IrimiaAlberto Lozano RosAna Beatriz Gago-VeigaFernando Velasco JuanesRuth RuscheweyhSimona SaccoElisa Cuadrado-GodiaDavid Garcia AzorinJulio PascualRaquel Gil-GouveiaMariano Huerta-VillanuevaJaime Rodriguez-VicoJavier Viguera RomeroVictor ObachSonia Santos-LasaosaMona Ghadiri-SaniCristina TassorelliJavier Díaz-de-TeránSamuel Díaz InsaCarmen González OriaPiero BarbantiPatricia Pozo-Rosichnull nullPublished in: Journal of neurology, neurosurgery, and psychiatry (2024)
This is the largest real-world study of migraine patients treated with anti-CGRP MAbs. It provides evidence that higher migraine frequency and greater disability at baseline reduce the likelihood of responding to anti-CGRP MAbs, informing physicians and policy-makers on the need for an earlier treatment in order to offer the best chance of treatment success.